Novel 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid sesquihydrate (ATT-2266 sesquihydrate).
The aforesaid compound can be prepared by heating 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthydrine-3-carboxylic acid at a temperature above about 60°C in the presence of water in an amount enough to form the sesquihydrate.
This sesquihydrate is much more stable than the anhydrate and the trihydrate and is superior to the anhydrate in the rate of dissolution and transference into the body through the intestines. The antibacterial activities in vitro and in vivo of the sesquihydrate are essentially same with those of known AT-2266. Thus, it is especially useful as a pharmaceutical compound.
新型 1-乙基-6-
氟-1,4-二氢-4-氧代-7-(1-
哌嗪基)-
1,8-萘啶-3-羧酸倍半
水合物(A
TT-2266 倍半
水合物)。
上述化合物可通过加热 1-乙基-6-
氟-1,4-二氢-4-氧代-7-(1-
哌嗪基)-
1,8-萘啶-3-羧酸来制备,加热温度应高于约 60°C,加热时应加入足以形成倍半
水合物的
水。
这种倍半
水合物比无
水物和三
水合物稳定得多,在溶解和通过肠道进入人体的速度方面也优于无
水物。倍半
水合物在体外和体内的抗菌活性与已知的 AT-2266 基本相同。因此,它作为药物化合物特别有用。